Clinical Trial Detail

NCT ID NCT03162536
Title Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors ArQule
Indications

mantle cell lymphoma

lymphoma

non-Hodgkin lymphoma

diffuse large B-cell lymphoma

chronic lymphocytic leukemia

Waldenstroem's macroglobulinemia

CLL/SLL

Therapies

ARQ 531

Age Groups: adult senior

No variant requirements are available.